Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials

References

• Bearelly S, Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin. 2004;44(4):85–102. doi:10.1097/00004397-200404440-00008.
   PubMedGoogle Scholar
• Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795–802. doi:10.1016/j.ophtha.2012.09.032.
   PubMed Web of Science ®Google Scholar
• Group TBVOS. Argon laser photocoagulation for macular edema in branch vein occlusion. The branch vein occlusion study group. Am J Ophthalmol. 1984;98(3):271–82. doi:10.1016/0002-9394(84)90316-7.
   PubMed Web of Science ®Google Scholar
• Jonas J, Paques M, Mones J, Glacet-Bernard A. Retinal vein occlusions. Dev Ophthalmol. 2010;47:111–135.
   PubMedGoogle Scholar
• Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363(22):2135–44. doi:10.1056/NEJMcp1003934.
   PubMed Web of Science ®Google Scholar
• Prasad PS, Oliver SC, Coffee RE, Hubschman JP, Schwartz SD. Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology. 2010;117(4):780–84. doi:10.1016/j.ophtha.2009.09.019.
   PubMed Web of Science ®Google Scholar
• Singer M, Tan CS, Bell D, Sadda SR. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina. 2014;34(9):1736–42. doi:10.1097/IAE.0000000000000148.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion-iii. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488–506. doi:10.1016/s0161-6420(83)34542-5.
   PubMed Web of Science ®Google Scholar
• Weinberg DV, Wahle AE, Ip MS, Scott IU, VanVeldhuisen PC, Blodi BA. Score study report 12: development of venous collaterals in the score study. Retina. 2013;33(2):287–95. doi:10.1097/IAE.0b013e318263d106.
   PubMed Web of Science ®Google Scholar
• Group TCVOS. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol. 1997;115(4):486–91.
   PubMedGoogle Scholar
• Yasuda S, Kachi S, Kondo M, Ueno S, Kaneko H, Terasaki H. Significant correlation between retinal venous tortuosity and aqueous vascular endothelial growth factor concentration in eyes with central retinal vein occlusion. PLoS One. 2015;10(7):e0134267. doi:10.1371/journal.pone.0134267.
   PubMed Web of Science ®Google Scholar
• Berger AR, Cruess AF, Altomare F, Chaudhary V, Colleaux K, Greve M, Kherani A, Mandelcorn ED, Parsons H, Rheaume MA, et al. Optimal treatment of retinal vein occlusion: canadian expert consensus. Ophthalmologica. 2015;234(1):6–25. doi:10.1159/000381357.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Amoaku WM, Hykin P. The royal college of ophthalmologists guidelines on retinal vein occlusions: executive summary. Eye (Lond). 2015;29(12):1633–38. doi:10.1038/eye.2015.164.
   PubMed Web of Science ®Google Scholar
• Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, Lu C, Katz TA, Schmidt-Erfurth U. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the view trials. Ophthalmology. 2016;123(7):1521–29. doi:10.1016/j.ophtha.2016.03.037.
   PubMed Web of Science ®Google Scholar
• Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, et al. Head-to-head comparison of ranibizumab prn versus single-dose dexamethasone for branch retinal vein occlusion (comrade-b). Acta Ophthalmol. 2018;96(1):e10–e18. doi:10.1111/aos.13381.
   PubMed Web of Science ®Google Scholar
• Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (comrade c): A european label study. Am J Ophthalmol. 2016;169(258–267). doi:10.1016/j.ajo.2016.04.020.
   Web of Science ®Google Scholar
• Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina. 2016;36(12):2319–28. doi:10.1097/IAE.0000000000001070.
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of brighter. Ophthalmology. 2016;123(6):1332–44. doi:10.1016/j.ophtha.2016.02.030.
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the brighter study. Ophthalmology. 2017;124(12):1778–87. doi:10.1016/j.ophtha.2017.06.027.
   PubMed Web of Science ®Google Scholar
• Larsen M, Waldstein SM, Boscia F, Gerding H, Mones J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the crystal study. Ophthalmology. 2016;123(5):1101–11. doi:10.1016/j.ophtha.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Petruzzi G, Parravano M, Varano M, Bandello F. Dexamethasone implant for macular edema secondary to ischemic retinal vein occlusions. Retina. 2015;35(7):1387–92. doi:10.1097/IAE.0000000000000492.
   PubMed Web of Science ®Google Scholar
• Chatziralli I, Nicholson L, Vrizidou E, Koutsiouki C, Menon D, Sergentanis TN, Citu MC, Hamilton R, Patel PJ, Hykin P, et al. Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmology. 2016;123(8):1762–70. doi:10.1016/j.ophtha.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Singh RP, Lee TJ, Yau L, Rubio RG. Collateral vessel presence in branch and central retinal vein occlusions and their impact on visual acuity and anatomical gains: A retrospective analysis. Retina. 2014;34(11):2242–49. doi:10.1097/IAE.0000000000000209.
   PubMed Web of Science ®Google Scholar
• EMA/SmPC. European medicines agency. Summary of product characteristics. Lucentis 10 mg/ml solution for injection. Novartis; 2015. [accessed 2016 May 18]. http://www.Ema.Europa.Eu/docs/en_gb/document_library/epar_-_product_information/human/000715/wc500043546.Pdf.
   Google Scholar
• Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: A systematic review. PLoS One. 2013;8(10):e78538. doi:10.1371/journal.pone.0078538.
   PubMed Web of Science ®Google Scholar
• Ehlken C, Grundel B, Michels D, Junker B, Stahl A, Schlunck G, Hansen LL, Feltgen N, Martin G, Agostini HT, et al. Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion. PLoS One. 2015;10(5):e0126859. doi:10.1371/journal.pone.0126859.
   PubMed Web of Science ®Google Scholar
• Ehlken C, Rennel ES, Michels D, Grundel B, Pielen A, Junker B, Stahl A, Hansen LL, Feltgen N, Agostini HT, et al. Levels of vegf but not vegf(165b) are increased in the vitreous of patients with retinal vein occlusion. Am J Ophthalmol. 2011;152(2):298–303 e291. doi:10.1016/j.ajo.2011.01.040.
   PubMed Web of Science ®Google Scholar
• Hua J, Spee C, Kase S, Rennel ES, Magnussen AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, Harper SJ, et al. Recombinant human vegf165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51(8):4282–88. doi:10.1167/iovs.09-4360.
   PubMed Web of Science ®Google Scholar
• Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, et al. Vegf-a165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci. 2010;51(8):4273–81. doi:10.1167/iovs.09-4296.
   PubMed Web of Science ®Google Scholar
• Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103. doi:10.1111/j.1755-3768.2011.02292.x.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, Eguchi S. Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: A case control series. J Inflamm (Lond). 2011;8(38). doi:10.1186/1476-9255-8-36.
   PubMed Web of Science ®Google Scholar